Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 101 clinical trials
KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

with advanced squamous or non-squamous NSCLC. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

carboplatin
carboplatin/paclitaxel
targeted therapy
cancer chemotherapy
pemetrexed
  • 2 views
  • 26 Apr, 2021
  • 25 locations
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-5890 or MK-4830 in participants with advanced squamous or non-squamous NSCLC that

cancer chemotherapy
platinum doublet
pembrolizumab
lung carcinoma
targeted therapy
  • 11 views
  • 27 Apr, 2021
  • 25 locations
Staggered Chemo-Immunotherapy With Durvalumab MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer. The study will focus on the efficacy of two alternative staggered dosing regimens.

cancer
platelet count
carboplatin
measurable disease
gilbert's syndrome
  • 0 views
  • 24 Jan, 2021
  • 1 location
Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

A Controlled Clinical Study of Endostar/PD-1 Inhibitors Combined With chemotherapy(Carboplatin-Pemetrexed) as First-line Treatment for Advanced Non-squamous Cell Lung Cancer With Negative Driving Gene

  • 0 views
  • 23 Jan, 2021
  • 1 location
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

The study for innovative strategies is warranted in the treatment of advanced non-squamous NSCLC with epidermal growth factor receptor wild-type or unknown mutation status because the outcomes

  • 0 views
  • 23 Jan, 2021
  • 2 locations
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

-IV Non-squamous non-small-cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Del19 and L858R). Safety and tolerability of Apatinib in combination with

  • 12 views
  • 21 Jan, 2021
  • 70 views
  • 08 May, 2021
  • 16 locations
Durvalumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. We hypothesized that Durvalumab in combination with standard chemotherapy is safe and effective

  • 0 views
  • 26 Jan, 2021
  • 2 locations
Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

This is a phase II clinical trial aimed at evaluating the efficacy of PD-L1 inhibition with atezolizumab in advanced squamous and non-squamous NSCLC patients previously treated with anti-PD-1

  • 22 views
  • 26 Jan, 2021
  • 2 locations
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

non-small cell lung cancer with progression on or after platinum-based chemotherapy. Plinabulin inhibits tumor growth by targeting both new and existing blood vessels going to the tumor as well

brain metastases
cancer
measurable disease
nivolumab
squamous non-small cell lung cancer
  • 0 views
  • 01 Mar, 2021
  • 1 location